Your browser doesn't support javascript.
loading
Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma.
Goto, Hideki; Makita, Shinichi; Kato, Koji; Tokushige, Kota; Fujita, Taizo; Akashi, Koichi; Izutsu, Koji; Teshima, Takanori.
Afiliação
  • Goto H; Department of Hematology, Graduate School of Medicine, Hokkaido University Faculty of Medicine, Sapporo, Japan. hidekigt@med.hokudai.ac.jp.
  • Makita S; Department of Hematology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
  • Kato K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
  • Tokushige K; Novartis Pharma K.K., Toranomon Minato-ku, Tokyo, Japan.
  • Fujita T; Novartis Pharma K.K., Toranomon Minato-ku, Tokyo, Japan.
  • Akashi K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
  • Izutsu K; Department of Hematology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
  • Teshima T; Department of Hematology, Graduate School of Medicine, Hokkaido University Faculty of Medicine, Sapporo, Japan.
Int J Clin Oncol ; 25(9): 1736-1743, 2020 Sep.
Article em En | MEDLINE | ID: mdl-32448949

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfoma Difuso de Grandes Células B / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfoma Difuso de Grandes Células B / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article